Atlanta, GA, March 14, 2014 – Matrix Surgical USA, a leader in the development, manufacturing and commercialization of craniomaxillofacial implants, announced today that it has entered into a definitive agreement with Dr. Michael J. Yaremchuk to license a patent-pending craniofacial implant system (US patent application 20120330427).
Under the terms of the agreement, Matrix Surgical USA will use its proprietary technology to manufacture implants designed by Dr. Yaremchuk for use in craniofacial reconstruction and augmentation procedures. Through the collaboration, Dr. Yaremchuk and Matrix Surgical USA will use their complementary clinical and engineering capabilities to develop and manufacture next-generation implant shapes that provide better outcomes for plastic surgeons and their patients.
“We are excited to extend our working relationship with Dr. Yaremchuk,” said John O’Shaughnessy, Founder and Chief Executive Officer of Matrix Surgical USA. “Building stronger collaborative relationships with leading surgeons like Dr. Yaremchuk is important to the Company’s future. This relationship expands our opportunities to deliver best-in-class products and fits well with Dr. Yaremchuk’s clinical practice to provide leading-edge solutions to improve people’s lives.”
The suite of implants designed by Dr. Yaremchuk and manufactured by the Company will be marketed under the OMNIPORE® brand and sold worldwide through Matrix Surgical USA’s global distribution network.
Manufactured in the USA, OMNIPORE High-density Porous Polyethylene craniofacial implants are used for reconstructive and aesthetic craniofacial surgery, have FDA clearance and CE Mark approval, and the company is ISO 13485:2003 certified.